NCT06550882Recruiting
A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea
Post-Marketing Surveillance (Use-result Surveillance) of OBIZUR Injection [Susoctocog Alpha (Porcine Antihemophilic Factor VIII, Recombinant)] for the Approved Indications in South Korea
Source: ClinicalTrials.gov · Last updated 11 Sept 2026
Brief summary (registry, in English)
Acquired hemophilia A (AHA) is a rare bleeding condition which prevents blood clotting. Acquired means that people are not born with this condition or have a family history of blood clotting conditions. People living with AHA can have sudden and severe bleeding. They also have longer bleeding compared to people without AHA. The main aim of the study is to learn how safe OBIZUR is in adults with AHA. Other aims are to see how effective OBIZUR is to control bleeding and how treatment is used in a routine clinical practice setting. The treatment of the participants will be determined by the treating physicians. During the study, data already existing in the participants' medical record and new data will be collected.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 9 (estimated)
- First submitted
- 9 Aug 2024
- Start date
- 22 Jul 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Takeda
- Diseases
- Haemophilia
- NCT number
- NCT06550882
What you commit to
- Study type: Observational
- Planned participants: 9
- From 22 Jul 2025 to the primary completion date, 31 Dec 2026
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants with Congenital Hemophilia A with Inhibitors (CHAWI).
- Participants who has participated in another clinical study involving a medicinal product or device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving a medicinal product or device during the course of the study.
Other illness
- Participants with hypersensitivity to any of the components of this drug.
Other
- Participants for whom Obizur treatment is contraindicated as per product label.
Who the study is looking for
- Participants with AHA.
- Participants who are determined to have the clinical need to receive Obizur treatment.
- Participants aged 18 years or older at time of initiation of Obizur treatment.
- Participants agreed to participate in the study and voluntarily signed the informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kyung Hee University Hospital at Gangdong Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
| The Catholic University of Korea, Seoul ST. Mary's Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
| Ewha Womans University Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
| Ulsan University Hospital Coordinator of this site? Confirm its status | Ulsan | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.